To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with JavaScript enabled.
This website is not optimized for your browser, as configured.

Lilly’s COVID-19 Clinical Trials are Underway

Editor’s note: Dan Skovronsky is the chief scientific officer and head of research and development at Eli Lilly and Company.

The rush to find effective medications to treat and potentially prevent COVID-19 is on. In fact, it has been on for several months now, since COVID-19 was first identified. And this rush is sparking unprecedented global medical and scientific collaboration and partnership.

As researchers, we aren’t racing against each other. We’re racing against the death toll from the virus. Ultimately, I hope that there will be multiple successful treatment options for patients and their healthcare providers. But before new treatments can be used broadly, we need to demonstrate their safety and efficacy through clinical trials. Thanks to a common purpose and partnerships across government, industry, and academia, these studies are moving at an extraordinary pace and scale.

Earlier this month, Lilly began clinical trials to test two antibodies engineered from patients who had fought COVID-19 and recovered. Antibodies are produced by the immune system in response to bacteria, viruses, and other foreign invaders, and help the body neutralize and destroy these threats. However, it takes time for the body to produce its own antibodies, and we are testing whether administering an antibody engineered from a COVID-19 survivor can speed recovery, or maybe even prevent infection in the first place.

The science behind this approach is not new. In fact, the practice of using convalescent plasma, which is the liquid part of the blood that contains antibodies, to treat various medical conditions has been around for decades. However, because convalescent plasma must be obtained from individual donors, it cannot be scaled broadly and its effectiveness varies between individual donors. Thankfully, advances in biotechnology now allow us to quickly identify the superstar antibodies from patients who have recovered from COVID-19, and mass produce them in sophisticated bioreactors.

Multiple companies and universities are pursuing such antibodies, and several have been shown to have a neutralizing effect in laboratory studies — blocking the COVID-19 virus from infecting cultured cells and replicating. Recently, one was shown to rapidly reduce virus levels in infected animals, and to prevent infection in animals that were pretreated with the antibody.

Lilly is testing the safety and efficacy of three different antibodies in hundreds, perhaps thousands, of people.

These antibodies — once proven safe and effective - may provide a good option for medical care of COVID-19 patients by both treating active disease and potentially preventing new infections through passive immunity. It’s fascinating to look back at statements from Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, from a few years ago where he describes this exact scenario. (Take a moment to listen to this interview from the New England Journal of Medicine from 2018.)

In the long run, the better solution is to protect people with effective COVID-19 vaccines, once they are available, and reserve antibody treatments for people who have the disease, were recently exposed, or belong to a group with key risk factors. But it will likely be some time before vaccines are available for everyone.

Let’s consider a scenario very much in the here and now:

Imagine you are an otherwise healthy individual, with a job that involves regular contact with other people. You wake up feeling unwell with a slight cough, sore throat, and headache. But you don’t feel all that sick, and even if you have COVID-19, you know you’ll mostly likely recover on your own. Still, there is a small chance you will need to be hospitalized, or even die from the disease. The reality is, we don’t know what causes some people to be more vulnerable than others. For this reason, it’s important to seek testing, speak with a healthcare professional, and avoid contact with others. But now you can do more than that; you can consider participating in clinical research. In doing so, you’ll help advance the body of scientific and medical knowledge, and may help us find the treatment we need. The rush is on, but we need your help.

COVID-19ResearchTypes ButtonsLTG 19May2020

COVID-19ResearchTypes ButtonsCTgov 19May2020

Keep up with the latest news on our progress in COVID-19: 2021 Updates: Lilly's Global COVID-19 Response | Eli Lilly and Company.

Tags: COVID-19, Clinical Research,

Recent Articles

From Alzheimer’s Diagnosis to Advocate

LTGBlogAuthors GuestAuthorIcon 20July2018
Guest Author
January 31st, 20225 minute read

Geri had been involved in research in addition to having a healthcare background. Because of this, after being diagnosed with Alzheimer's she knew that she wanted to participate in a clinical trial.

Committed to Cancer Research

Leigh Anne Naas Headshot
Leigh Anne Naas
September 24th, 20211 minute read

Lilly has a strong legacy in cancer research. Our dedicated oncology team work together to create medicines that make life better for people around the world.

Proud Partners in Breast Cancer Research

Leigh Anne Naas Headshot
Leigh Anne Naas
September 22nd, 20213 minute read

Lilly is proud to foster true partnerships with external stakeholders. By working together to raise awareness of breast cancer research, we can make life better for people around the world.

Recommendations for Decentralized Clinical Trial Capabilities in the Wake of COVID-19

Kevin Hudziak
September 15th, 20214 minute read

Tips to implement an effective and successful decentralized clinical trial for multiple touch points.

The COVID-19 Pandemic Changed How Sites Conduct Clinical Trials Forever

Kevin Hudziak
July 29th, 20213 minute read

To better understand how various countries adapted to execute clinical trials during a pandemic, we conducted a series of virtual feedback sessions with clinicians from all over the world.

This site is intended for US residents.
This site is intended for US residents.